Regeneron, too, is working on a PD-1 inhibitor, with its REGN2810. It's developing this in partnership with Sanofi ( SNY ). In June, Regeneron and Sanofi said 46.2% of patients with a form of skin cancer responded to treatment with REGN2810 in a Phase 1 trial.